No Data
No Data
China Approves Lukang Pharma's Anti-Asthma Injection
China's medical products administrator approved Shandong Lukang Pharmaceutical's (SHA:600789) doxofylline bronchodilator injection indicated for asthma, according to a Wednesday filing with the Shangh
Express News | Lukang Pharmaceutical: The holding subsidiary obtained a dosofylline injection drug registration certificate
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
Lukang Pharmaceutical dropped 8.78% today, and Fang Xinxia's net purchase of seats was 49.73 million yuan
Lukang Pharmaceutical dropped 8.78% today, with a turnover of 2,978 billion yuan, and a turnover rate of 33.43%. After-market data showed that Fang Xinxia's net purchase of seats was 49.73 million yuan, while the Shanghai Stock Connect exclusive seat bought 31.8072 million yuan and sold 32.824,400 yuan.
Lukang Pharmaceuticals fell more than 8% in the market, with a turnover of over 2.5 billion yuan.
Lukang Pharmaceuticals fell more than 8% in the market, with a turnover of over 2.5 billion yuan.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
No Data